ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Merus still hopes for a future for MCLA-129, but the doors are closing.